Crescendo Biologics to Present Poster at AACR Annual Meeting 18 April 2018

Cambridge, UK, 20 March 2018 – Crescendo Biologics Limited (Crescendo), the drug developer of novel, targeted T-cell engaging therapeutics, announces that Dr Brian McGuinness, Head of New Product and Business Development, Phil Bland-Ward (CSO) and James Legg (VP R&D) will be presenting a poster at AACR (American Association for Cancer Research) Annual Meeting in Chicago, USA on 18 April 2018.

The Crescendo team will be available to discuss the poster entitled “Multifunctional biologics for targeted T-cell therapy based on in vivo matured fully human VH domains” within the “Antibodies, Fusion Proteins and Related Biologics session”. This will cover the beneficial characteristics of Humabodies and their enhanced therapeutic potential over traditional monoclonal antibodies.

Poster details

Title: Multifunctional biologics for targeted T-cell therapy based on in vivo matured fully human VH domains
Authors: J. Legg, B. McGuinness, P. Bland-Ward, P. Pack
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibodies, Fusion Proteins, and Related Biologics
Session Date and Time: Wednesday Apr 18, 2018 8:00 AM - 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 35
Poster Board Number: 11
Permanent Abstract Number: 5766

There will also be a poster by Eleven Biotherapeutics in the same session which includes data from Crescendo. This poster, entitled ‘Engineering and characterization of anti-PSMA humabody-deBouganin fusion proteins’, will be at Board Number 15.

AACR’s Annual Meeting is being held in Chicago, Illinois from 14 – 18 April. The theme is ‘Driving Innovative Cancer Science to Patient Care’. Presentations at the Annual Meeting will cover the latest basic, translational, clinical, and prevention-focused research in the field, including important areas such as early detection, cancer interception, and survivorship in all populations.

Ends

For more information, please contact:

Crescendo Biologics
Dr Peter Pack, CEO
Tel: 44 (0)1223 497140
info@crescendobiologics.com
Notes to Editors:

About Crescendo Biologics Ltd

Crescendo Biologics is a biopharmaceutical company developing potent, highly differentiated multi-functional Humabody® therapeutics in oncology, with an internal focus on biologics for Targeted T-cell Therapy with novel modes-of-action. It is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships, in both multi-functional immuno-oncology modulators and Humabody® Drug Conjugates (HDCs), the next generation of ADCs.

The Company’s Humabody® therapeutics are based on its unique, patent protected, transgenic mouse platform, generating 100% human V\text{H} domain building blocks (Humabody® V\text{H}) comprising the full structural diversity of the human V\text{H} repertoire and superior biophysical properties as a result of their in vivo maturation.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations), Takeda and Astellas.

For more information, please visit the website: [www.crescendobiologics.com](http://www.crescendobiologics.com)